

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
12 September 2003 (12.09.2003)

PCT

(10) International Publication Number  
WO 03/074491 A1(51) International Patent Classification<sup>7</sup>: C07D 231/14,  
231/16, 409/12, 405/12, 207/34, 277/56, 417/12, 213/82,  
327/06, 411/12, A01N 43/56, 43/36, 43/78, 43/40, 43/32(74) Agent: OSBORN, Martin, Keith; Intellectual Property  
Dept., Syngenta Limited, P.O. Box 3538, Jealott's Hill Re-  
search Centre, Bracknell, RG42 6YA (GB).

(21) International Application Number: PCT/IB03/00687

(22) International Filing Date: 21 February 2003 (21.02.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

0205127.4 5 March 2002 (05.03.2002) GB  
0300705.1 13 January 2003 (13.01.2003) GB(71) Applicant (for all designated States except US): SYN-  
GENTA PARTICIPATIONS AG [CH/CH]; Intellectual  
Property Department, Schwarzwaldallee 215, 4058 Basel  
(CH).

(72) Inventors; and


(75) Inventors/Applicants (for US only): EHRENFREUND,  
Josef [AT/CH]; Schwarzwaldallee 215, CH-4058 Basel  
(CH). TOBLER, Hans [CH/CH]; Schwarzwaldallee  
215, 4058 Basel (CH). WALTER, Harald [DE/CH];  
Schwarzwaldallee 215, CH-4058 Basel (CH).(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE,  
SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,  
VC, VN, YU, ZA, ZM, ZW.(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI,  
SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN,  
GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: O-CYCLOPROPYL-CARBOXANILIDES AND THEIR USE AS FUNGICIDES

(57) Abstract: A compound of formula (I): F1 Het is a 5- or 6-membered heterocyclic ring containing one to three heteroatoms, each independently selected from oxygen, nitrogen and sulphur, the ring being substituted by groups R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup>; R<sup>1</sup> is hydrogen or halo; R<sup>2</sup> is hydrogen or halo; R<sup>3</sup> is optionally substituted C<sub>2-12</sub> alkyl, optionally substituted C<sub>2-12</sub> alkenyl, optionally substituted C<sub>2-12</sub> alkynyl, optionally substituted C<sub>3-12</sub> cycloalkyl, optionally substituted phenyl or optionally substituted heterocyclyl; and R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> are, independently, selected from hydrogen, halo, cyano, nitro, C<sub>1-4</sub> haloalkyl, C<sub>1-4</sub> alkoxy (C<sub>1-4</sub>) alkoxy (C<sub>1-4</sub>) alkyl and C<sub>1-4</sub> haloalkoxy (C<sub>1-4</sub>) alkyl, provided that at least one of R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> is not hydrogen. The compounds of formula (I) have plant-protective


properties and are suitable for protecting plants against infestations by phytopathogenic microorganisms.

## O-CYCLOPROPYL-CARBOXANILIDES AND THEIR USE AS FUNGICIDES

The present invention relates to novel ortho-substituted-cyclopropyl-azol-carboxamides which have microbiocidal activity, in particular fungicidal activity. The invention also relates to the preparation of these compounds, to novel intermediates used in the preparation of these compounds, to agrochemical compositions which comprise at least one of the novel compounds as active ingredient, to the preparation of the compositions mentioned and to the use of the active ingredients or compositions in agriculture or horticulture for controlling or preventing infestation of plants by phytopathogenic microorganisms, preferably fungi.

EP0545099A2, JP06220035 and JP02129171 disclose certain ortho-unsubstituted-cyclopropyl-azol-carboxamides

The present invention provides a compound of formula (I):



Het is a 5- or 6-membered heterocyclic ring containing one to three heteroatoms, each independently selected from oxygen, nitrogen and sulphur, the ring being substituted by groups  $R^4$ ,  $R^5$  and  $R^6$ ;  $R^1$  is hydrogen or halo;  $R^2$  is hydrogen or halo;  $R^3$  is optionally substituted  $C_{2-12}$  alkyl, optionally substituted  $C_{2-12}$  alkenyl, optionally substituted  $C_{2-12}$  alkynyl, optionally substituted  $C_{3-12}$  cycloalkyl, optionally substituted phenyl or optionally substituted heterocyclyl; and  $R^4$ ,  $R^5$  and  $R^6$  are, independently, selected from hydrogen, halo, cyano, nitro,  $C_{1-4}$  alkyl,  $C_{1-4}$  haloalkyl,  $C_{1-4}$  alkoxy( $C_{1-4}$ )alkyl and  $C_{1-4}$  haloalkoxy( $C_{1-4}$ )alkyl, provided that at least one of  $R^4$ ,  $R^5$  and  $R^6$  is not hydrogen.

Halo is fluoro, chloro or bromo.

Each alkyl moiety is a straight or branched chain and is, for example, methyl, ethyl, *n*-propyl, *n*-butyl, *n*-pentyl, *n*-hexyl, *iso*-propyl, *n*-butyl, *sec*-butyl, *iso*-butyl, *tert*-butyl or *neo*-pentyl.

When present, each optional substituent on an alkyl moiety is, independently, selected from halo, hydroxy, cyano,  $C_{1-4}$ alkoxyC(=O), formyl, nitro,  $C_{1-4}$  alkoxy,

C<sub>1-4</sub> haloalkoxy, C<sub>1-4</sub> alkylthio, C<sub>1-4</sub> haloalkylthio, HC(OR')=N and R'R''NN=C(H); where R' and R'' are, independently, hydrogen or C<sub>1-4</sub> alkyl.

Alkenyl and alkynyl moieties can be in the form of straight or branched chains. The alkenyl moieties, where appropriate, can be of either the (E)- or (Z)-configuration.

5 Examples are vinyl, allyl and propargyl.

When present, each optional substituent on alkenyl or on alkynyl is, independently, selected from those optional substituents given above for an alkyl moiety.

Cycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.

10 When present, each optional substituent on cycloalkyl is, independently, selected from C<sub>1-3</sub> alkyl and those optional substituents given above for an alkyl moiety.

The term heterocyclyl refers to a non-aromatic or aromatic ring containing up to 10 atoms including one or more (preferably one or two) heteroatoms selected, each independently, from O, S and N. Examples of such rings include 1,3-dioxolanyl, tetrahydrofuranyl, morpholinyl, thienyl and furyl.

15 When present, each optional substituent on phenyl or on heterocyclyl is, independently, selected from C<sub>1-6</sub> alkyl and those optional substituents given above for an alkyl moiety. When present, there are up to four optional substituents on phenyl, each independently selected.

20 When present, each optional substituent on an alkyl moiety is, independently, selected from the preferred list of halo, hydroxy, methoxy, trifluoromethoxy, difluoromethoxy, cyano and nitro.

When present, each optional substituent on alkenyl or on alkynyl is, independently, selected from the preferred list of halo and cyano.

25 When present, each optional substituent on cycloalkyl is, independently, selected from the preferred list of methyl, ethyl, trifluoromethyl, methoxy, trifluoromethoxy and cyano.

When present, each optional substituent on phenyl or on a heterocyclyl group is, independently, selected from the preferred list of halo, hydroxy, methoxy, trifluoromethoxy, difluoromethoxy and cyano.


30 It is preferred that Het is pyrrolyl, pyrazolyl, thiazolyl, pyridinyl, pyrimidinyl, thiophenyl, furyl, isothiazolyl or isoxazolyl (more preferably pyrrolyl, pyrazolyl or thiazolyl), each being substituted by groups R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup>.

Preferably  $R^1$  and  $R^2$  are, independently, hydrogen or fluoro.

Preferably  $R^3$  is  $C_{2-6}$  alkyl, optionally substituted  $C_{3-8}$  cycloalkyl, phenyl, thienyl or furyl.

Preferably  $R^4$ ,  $R^5$  and  $R^6$  are, independently, selected from hydrogen, halogen,  $C_{1-4}$  alkyl,  $C_{1-4}$  haloalkyl and  $C_{1-4}$  alkoxy( $C_{1-4}$ )alkyl; provided that at least one of  $R^4$ ,  $R^5$  and  $R^6$  is not hydrogen. More preferably  $R^4$ ,  $R^5$  and  $R^6$  are, independently, selected from hydrogen, halogen, methyl,  $C_{1-2}$  haloalkyl and methoxymethyl; provided that at least one of  $R^4$ ,  $R^5$  and  $R^6$  is not hydrogen.

Compounds of formula (II):



where  $R^3$  is as defined above for a compound of formula (I), are also novel and are useful as intermediates in the preparation of compounds of formula (I).

Therefore, in another aspect the present invention provides a compound of formula (II) where  $R^3$  is as defined above for a compound of formula (I).

15 The compounds of formula (I) and of formula (II) may exist as different geometric or optical isomers or in different tautomeric forms. This invention covers all such isomers and tautomers and mixtures thereof in all proportions as well as isotopic forms such as deuterated compounds.

The compounds in Tables 1 to 6 below illustrate compounds of the invention.

20 Table 1 provides 22 compounds of formula (II) wherein  $R^3$  is as defined in Table

1.

Table 1

Compound Number	$R^3$
1.1	$CH_2CH_3$
1.2	$CH_2CH_2CH_3$
1.3	$CH(CH_3)_2$
1.4	$CH_2CH_2CH_2CH_3$
1.5	$CH_2CH(CH_3)_2$

1.6	$C(CH_3)_3$
1.7	$CH_2CH_2CH_2CH_2CH_3$
1.8	$CH_2CH_2CH(CH_3)_2$
1.9	$CH_2CH_2CH(CH_3)_2$
1.10	cyclopropyl
1.11	cyclobutyl
1.12	cyclopentyl
1.13	cyclohexyl
1.14	cycloheptyl
1.15	cyclooctyl
1.16	phenyl
1.17	p-Cl-phenyl
1.18	p-F-phenyl
1.19	p-Br-phenyl
1.20	thienyl
1.21	furyl
1.22	$\alpha$ -methylcyclopropyl

Table X represents Table 2 (when X is 2) and represents Table 3 (when X is 3).

Table X


Compound Number	$R^1$	$R^2$	$R^3$	$R^4$	$R^5$	$R^6$
X.1	H	H	$CH_2CH_3$	$CF_3$	$CH_3$	H
X.2	H	H	$CH_2CH_3$	$CF_3$	$CH_2OCH_3$	H
X.3	H	H	$CH_2CH_2CH_3$	$CF_3$	$CH_3$	H
X.4	H	H	$CH_2CH_2CH_3$	$CF_2H$	$CH_3$	H
X.5	H	H	$CH(CH_3)_2$	$CF_3$	$CH_3$	H
X.6	H	H	$CH(CH_3)_2$	$CF_2H$	$CH_3$	H
X.7	H	H	$CH(CH_3)_2$	$CFH_2$	$CH_3$	H
X.8	H	H	$CH(CH_3)_2$	$CH_3$	$CH_3$	Cl
X.9	H	H	$CH(CH_3)_2$	$CH_3$	$CH_2CH_3$	Cl

Compound Number	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	R <sup>6</sup>
X.10	H	H	CH(CH <sub>3</sub> ) <sub>2</sub>	CH <sub>3</sub>	CH <sub>3</sub>	F
X.11	H	H	CH(CH <sub>3</sub> ) <sub>2</sub>	CH <sub>3</sub>	CH <sub>2</sub> CH <sub>3</sub>	F
X.12	H	H	CH(CH <sub>3</sub> ) <sub>2</sub>	CF <sub>2</sub> Cl	CH <sub>3</sub>	F
X.13	H	H	CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>3</sub>	CF <sub>3</sub>	CH <sub>3</sub>	H
X.14	H	H	CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>3</sub>	CF <sub>2</sub> H	CH <sub>3</sub>	H
X.15	H	H	CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>3</sub>	CH <sub>3</sub>	CH <sub>3</sub>	F
X.16	H	H	CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>3</sub>	CH <sub>3</sub>	CH <sub>3</sub>	Cl
X.17	H	H	CH <sub>2</sub> CH(CH <sub>3</sub> ) <sub>2</sub>	CF <sub>3</sub>	CH <sub>3</sub>	H
X.18	H	H	CH <sub>2</sub> CH(CH <sub>3</sub> ) <sub>2</sub>	CF <sub>2</sub> H	CH <sub>3</sub>	H
X.19	H	H	CH <sub>2</sub> CH(CH <sub>3</sub> ) <sub>2</sub>	CFH <sub>2</sub>	CH <sub>3</sub>	H
X.20	H	H	CH <sub>2</sub> CH(CH <sub>3</sub> ) <sub>2</sub>	CF <sub>3</sub>	CH <sub>2</sub> OCH <sub>3</sub>	H
X.21	H	H	CH <sub>2</sub> CH(CH <sub>3</sub> ) <sub>2</sub>	CH <sub>3</sub>	CH <sub>3</sub>	F
X.22	H	H	CH <sub>2</sub> CH(CH <sub>3</sub> ) <sub>2</sub>	CH <sub>3</sub>	CH <sub>3</sub>	Cl
X.23	H	H	C(CH <sub>3</sub> ) <sub>3</sub>	CF <sub>3</sub>	CH <sub>3</sub>	H
X.24	H	H	C(CH <sub>3</sub> ) <sub>3</sub>	CF <sub>2</sub> H	CH <sub>3</sub>	H
X.25	H	H	C(CH <sub>3</sub> ) <sub>3</sub>	CF <sub>2</sub> H	CH <sub>3</sub>	H
X.26	H	H	C(CH <sub>3</sub> ) <sub>3</sub>	CH <sub>3</sub>	CH <sub>3</sub>	F
X.27	H	H	C(CH <sub>3</sub> ) <sub>3</sub>	CH <sub>3</sub>	CH <sub>3</sub>	Cl
X.28	H	H	C(CH <sub>3</sub> ) <sub>3</sub>	CF <sub>2</sub> Cl	CH <sub>3</sub>	H
X.29	H	H	CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>3</sub>	CF <sub>3</sub>	CH <sub>3</sub>	H
X.30	H	H	CH <sub>2</sub> CH <sub>2</sub> CH(CH <sub>3</sub> ) <sub>2</sub>	CF <sub>3</sub>	CH <sub>3</sub>	H
X.31	H	H	CH <sub>2</sub> CH <sub>2</sub> CH(CH <sub>3</sub> ) <sub>2</sub>	CF <sub>2</sub> H	CH <sub>3</sub>	H
X.32	H	H	CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>3</sub>	CF <sub>3</sub>	CH <sub>3</sub>	H
X.33	H	H	cyclopropyl	CF <sub>3</sub>	CH <sub>3</sub>	H
X.34	H	H	cyclopropyl	CF <sub>2</sub> H	CH <sub>3</sub>	H
X.35	H	H	cyclopropyl	CH <sub>3</sub>	CH <sub>3</sub>	F
X.36	H	H	cyclopropyl	CH <sub>3</sub>	CH <sub>3</sub>	Cl
X.37	H	H	cyclobutyl	CF <sub>3</sub>	CH <sub>3</sub>	H
X.38	H	H	cyclobutyl	CF <sub>2</sub> H	CH <sub>3</sub>	H

Compound Number	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	R <sup>6</sup>
X.39	H	H	cyclopentyl	CF <sub>3</sub>	CH <sub>3</sub>	H
X.40	H	H	cyclopentyl	CF <sub>2</sub> H	CH <sub>3</sub>	H
X.41	H	H	cyclopentyl	CFH <sub>2</sub>	CH <sub>3</sub>	H
X.42	H	H	cyclopentyl	CF <sub>2</sub> Cl	CH <sub>3</sub>	H
X.43	H	H	cyclopentyl	CH <sub>3</sub>	CH <sub>3</sub>	F
X.44	H	H	cyclopentyl	CH <sub>3</sub>	CH <sub>3</sub>	Cl
X.45	H	H	cyclohexyl	CF <sub>3</sub>	CH <sub>3</sub>	H
X.46	H	H	cyclohexyl	CF <sub>2</sub> H	CH <sub>3</sub>	H
X.47	H	H	cyclohexyl	CFH <sub>2</sub>	CH <sub>3</sub>	H
X.48	H	H	cyclohexyl	CF <sub>2</sub> Cl	CH <sub>3</sub>	H
X.49	F	F	cyclohexyl	CF <sub>3</sub>	CH <sub>3</sub>	H
X.50	H	H	cyclohexyl	CH <sub>3</sub>	CH <sub>3</sub>	F
X.51	H	H	cyclohexyl	CH <sub>3</sub>	CH <sub>3</sub>	Cl
X.52	H	H	cycloheptyl	CF <sub>3</sub>	CH <sub>3</sub>	H
X.53	H	H	cycloheptyl	CF <sub>3</sub>	CH <sub>2</sub> CH <sub>3</sub>	H
X.54	H	H	cycloheptyl	CF <sub>2</sub> H	CH <sub>3</sub>	H
X.55	H	H	cycloheptyl	CFH <sub>2</sub>	CH <sub>3</sub>	H
X.56	H	H	cycloheptyl	CF <sub>2</sub> Cl	CH <sub>3</sub>	F
X.57	H	H	cycloheptyl	CH <sub>3</sub>	CH <sub>3</sub>	F
X.58	H	H	cycloheptyl	CH <sub>3</sub>	CH <sub>3</sub>	Cl
X.59	H	H	cyclooctyl	CF <sub>3</sub>	CH <sub>3</sub>	H
X.60	H	H	cyclooctyl	CF <sub>2</sub> H	CH <sub>3</sub>	H
X.61	H	H	phenyl	CF <sub>3</sub>	CH <sub>3</sub>	H
X.62	H	H	phenyl	CF <sub>2</sub> H	CH <sub>3</sub>	H
X.63	H	H	phenyl	CFH <sub>2</sub>	CH <sub>3</sub>	H
X.64	H	H	phenyl	CH <sub>3</sub>	CH <sub>3</sub>	F
X.65	H	H	phenyl	CH <sub>3</sub>	CH <sub>3</sub>	Cl
X.66	H	H	4-fluorophenyl	CF <sub>3</sub>	CH <sub>3</sub>	H
X.67	H	H	4-fluorophenyl	CF <sub>2</sub> H	CH <sub>3</sub>	H

Compound Number	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	R <sup>6</sup>
X.68	H	H	4-chlorophenyl	CF <sub>3</sub>	CH <sub>3</sub>	H
X.69	H	H	4-chlorophenyl	CF <sub>2</sub> H	CH <sub>3</sub>	H
X.70	H	H	4-bromophenyl	CF <sub>3</sub>	CH <sub>3</sub>	H
X.71	H	H	4-bromophenyl	CF <sub>2</sub> H	CH <sub>3</sub>	H
X.72	H	H	2-thienyl	CF <sub>3</sub>	CH <sub>3</sub>	H
X.73	H	H	3-thienyl	CF <sub>3</sub>	CH <sub>3</sub>	H
X.74	H	H	2-furyl	CF <sub>3</sub>	CH <sub>3</sub>	H
X.75	H	H	2-furyl	CF <sub>3</sub>	CH <sub>3</sub>	H
X.76	H	H	$\alpha$ -methylcyclopropyl	CF <sub>3</sub>	CH <sub>3</sub>	H
X.77	H	H	$\alpha$ -methylcyclopropyl	CF <sub>2</sub> H	CH <sub>3</sub>	H
X.78	H	H	$\alpha$ -methylcyclopropyl	CH <sub>3</sub>	CH <sub>3</sub>	F
X.79	H	H	$\alpha$ -methylcyclopropyl	CH <sub>3</sub>	CH <sub>3</sub>	Cl
X.80	H	H	$\alpha$ -methylcyclopropyl	CF <sub>3</sub>	CH <sub>3</sub>	Cl


Table 2 provides 80 compounds of formula (1a):



wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> are as defined in Table 2.




Table 3 provides 80 compounds of formula (1b):



wherein  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$  and  $R^6$  are as defined in Table 3.

5 Table 4 provides 50 compounds of formula (1c):



wherein  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$  and  $R^5$  are as defined in Table 4.


Table 4

Compound Number	$R^1$	$R^2$	$R^3$	$R^4$	$R^5$
4.1	H	H	$\text{CH}_2\text{CH}_3$	$\text{CF}_3$	$\text{CH}_3$
4.2	H	H	$\text{CH}_2\text{CH}_3$	$\text{CH}_3$	$\text{CH}_3$
4.3	H	H	$\text{CH}_2\text{CH}_2\text{CH}_3$	$\text{CF}_3$	$\text{CH}_3$
4.4	H	H	$\text{CH}_2\text{CH}_2\text{CH}_3$	$\text{CH}_3$	$\text{CH}_3$
4.5	H	H	$\text{CH}(\text{CH}_3)_2$	$\text{CF}_3$	$\text{CH}_3$
4.6	H	H	$\text{CH}(\text{CH}_3)_2$	$\text{CH}_3$	$\text{CH}_3$
4.7	H	H	$\text{CH}(\text{CH}_3)_2$	$\text{CH}_2\text{CH}_3$	$\text{CH}_3$
4.8	H	H	$\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$	$\text{CF}_3$	$\text{CH}_3$
4.9	H	H	$\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$	$\text{CH}_3$	$\text{CH}_3$
4.10	H	H	$\text{CH}_2\text{CH}(\text{CH}_3)_2$	$\text{CF}_3$	$\text{CH}_3$
4.11	H	H	$\text{CH}_2\text{CH}(\text{CH}_3)_2$	$\text{CH}_3$	$\text{CH}_3$
4.12	H	H	$\text{C}(\text{CH}_3)_3$	$\text{CF}_3$	$\text{CH}_3$

Compound Number	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>
4.13	H	H	CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>3</sub>	CF <sub>3</sub>	CH <sub>3</sub>
4.14	H	H	CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>3</sub>	CH <sub>3</sub>	CH <sub>3</sub>
4.15	H	H	CH <sub>2</sub> CH <sub>2</sub> CH(CH <sub>3</sub> ) <sub>2</sub>	CF <sub>3</sub>	CH <sub>3</sub>
4.16	H	H	CH <sub>2</sub> CH <sub>2</sub> CH(CH <sub>3</sub> ) <sub>2</sub>	CH <sub>3</sub>	CH <sub>3</sub>
4.17	H	H	CH <sub>2</sub> CH <sub>2</sub> CH(CH <sub>3</sub> ) <sub>2</sub>	CH <sub>3</sub>	CH <sub>2</sub> CH <sub>3</sub>
4.18	H	H	CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>3</sub>	CF <sub>3</sub>	CH <sub>3</sub>
4.19	H	H	CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>3</sub>	CH <sub>3</sub>	CH <sub>3</sub>
4.20	H	H	cyclopropyl	CF <sub>3</sub>	CH <sub>3</sub>
4.21	H	H	cyclopropyl	CH <sub>3</sub>	CH <sub>3</sub>
4.22	H	H	cyclobutyl	CF <sub>3</sub>	CH <sub>3</sub>
4.23	H	H	cyclobutyl	CH <sub>3</sub>	CH <sub>3</sub>
4.24	H	H	cyclopentyl	CF <sub>3</sub>	CH <sub>3</sub>
4.25	H	H	cyclopentyl	CH <sub>3</sub>	CH <sub>3</sub>
4.26	H	H	cyclohexyl	CF <sub>3</sub>	CH <sub>3</sub>
4.27	H	H	cyclohexyl	CH <sub>3</sub>	CH <sub>3</sub>
4.28	H	H	cyclohexyl	CF <sub>3</sub>	CH <sub>2</sub> CH <sub>3</sub>
4.29	H	H	cycloheptyl	CF <sub>3</sub>	CH <sub>3</sub>
4.30	H	H	cycloheptyl	CH <sub>3</sub>	CH <sub>3</sub>
4.31	H	H	cyclooctyl	CF <sub>3</sub>	CH <sub>3</sub>
4.32	H	H	cyclooctyl	CH <sub>3</sub>	CH <sub>3</sub>
4.33	H	H	phenyl	CF <sub>3</sub>	CH <sub>3</sub>
4.34	H	H	phenyl	CH <sub>3</sub>	CH <sub>3</sub>
4.35	H	H	4-fluorophenyl	CF <sub>3</sub>	CH <sub>3</sub>
4.36	H	H	4-fluorophenyl	CH <sub>3</sub>	CH <sub>3</sub>
4.37	H	H	4-chlorophenyl	CF <sub>3</sub>	CH <sub>3</sub>
4.38	H	H	4-chlorophenyl	CH <sub>3</sub>	CH <sub>3</sub>
4.39	H	H	4-bromophenyl	CF <sub>3</sub>	CH <sub>3</sub>
4.40	H	H	4-bromophenyl	CH <sub>3</sub>	CH <sub>3</sub>
4.41	H	H	2-thienyl	CF <sub>3</sub>	CH <sub>3</sub>

Compound Number	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>
4.42	H	H	2-thienyl	CH <sub>3</sub>	CH <sub>3</sub>
4.43	H	H	3-thienyl	CF <sub>3</sub>	CH <sub>3</sub>
4.44	H	H	3-thienyl	CH <sub>3</sub>	CH <sub>3</sub>
4.45	H	H	2-furyl	CF <sub>3</sub>	CH <sub>3</sub>
4.46	H	H	2-furyl	CH <sub>3</sub>	CH <sub>3</sub>
4.47	H	H	3-furyl	CF <sub>3</sub>	CH <sub>3</sub>
4.48	H	H	3-furyl	CH <sub>3</sub>	CH <sub>3</sub>
4.49	H	H	$\alpha$ -methylcyclopropyl	CF <sub>3</sub>	CH <sub>3</sub>
4.50	H	H	$\alpha$ -methylcyclopropyl	CH <sub>3</sub>	CH <sub>3</sub>

Table 5 provides 54 compounds of formula (1d):



wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> are as defined in Table 5.

5


Table 5

Compound Number	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>
5.1	H	H	CH <sub>2</sub> CH <sub>3</sub>	Cl
5.2	H	H	CH <sub>2</sub> CH <sub>2</sub> CH <sub>3</sub>	Cl
5.3	H	H	CH <sub>2</sub> CH <sub>2</sub> CH <sub>3</sub>	Br
5.4	H	H	CH <sub>2</sub> CH <sub>2</sub> CH <sub>3</sub>	CF <sub>3</sub>
5.5	H	H	CH(CH <sub>3</sub> ) <sub>2</sub>	Cl
5.6	H	H	CH(CH <sub>3</sub> ) <sub>2</sub>	Br
5.7	H	H	CH(CH <sub>3</sub> ) <sub>2</sub>	CF <sub>3</sub>
5.8	H	H	CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>3</sub>	Cl
5.9	H	H	CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>3</sub>	Br

Compound Number	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>
5.10	H	H	CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>3</sub>	CF <sub>3</sub>
5.11	H	H	C(CH <sub>3</sub> ) <sub>3</sub>	Cl
5.12	H	H	CH <sub>2</sub> CH(CH <sub>3</sub> ) <sub>2</sub>	Cl
5.13	H	H	CH <sub>2</sub> CH(CH <sub>3</sub> ) <sub>2</sub>	Br
5.14	H	H	CH <sub>2</sub> CH(CH <sub>3</sub> ) <sub>2</sub>	CF <sub>3</sub>
5.15	H	H	CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>3</sub>	Cl
5.16	H	H	CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>3</sub>	Br
5.17	H	H	CH <sub>2</sub> CH <sub>2</sub> CH(CH <sub>3</sub> ) <sub>2</sub>	Cl
5.18	H	H	CH <sub>2</sub> CH <sub>2</sub> CH(CH <sub>3</sub> ) <sub>2</sub>	Br
5.19	H	H	CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>3</sub>	Cl
5.20	H	H	CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>3</sub>	Br
5.21	H	H	cyclopropyl	Cl
5.22	H	H	cyclopropyl	Br
5.23	H	H	cyclobutyl	Cl
5.24	H	H	cyclobutyl	Br
5.25	H	H	cyclopentyl	Cl
5.26	H	H	cyclopentyl	Br
5.27	F	F	cyclopentyl	CF <sub>3</sub>
5.28	H	H	cyclohexyl	Cl
5.29	H	H	cyclohexyl	Br
5.30	H	H	cyclohexyl	CF <sub>3</sub>
5.31	H	H	cycloheptyl	Cl
5.32	H	H	cycloheptyl	Br
5.33	H	H	cycloheptyl	CF <sub>3</sub>
5.34	H	H	cyclooctyl	Cl
5.35	H	H	phenyl	Cl
5.36	H	H	phenyl	Br
5.37	H	H	4-fluorophenyl	Cl
5.38	H	H	4-fluorophenyl	Br

Compound Number	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>
5.39	H	H	4-fluorophenyl	CF <sub>3</sub>
5.40	H	H	4-chlorophenyl	Cl
5.41	H	H	4-chlorophenyl	Br
5.42	H	H	4-chlorophenyl	CF <sub>3</sub>
5.43	H	H	4-bromophenyl	Cl
5.44	H	H	2-thienyl	Cl
5.45	H	H	2-thienyl	Br
5.46	H	H	3-thienyl	Cl
5.47	H	H	3-thienyl	Cl
5.48	H	H	2-furyl	Cl
5.49	H	H	2-furyl	Br
5.50	H	H	3-furyl	Cl
5.51	H	H	3-furyl	Br
5.52	H	H	2-pyridyl	Cl
5.53	H	H	$\alpha$ -methylcyclopropyl	Cl
5.54	H	H	$\alpha$ -methylcyclopropyl	Br

Table 6 provides 45 compounds of formula (1e):



wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> are as defined in Table 6.

Table 6

Compound Number	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>

Compound Number	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>
6.1	H	H	CH <sub>2</sub> CH <sub>3</sub>	CH <sub>3</sub>
6.2	H	H	CH <sub>2</sub> CH <sub>2</sub> CH <sub>3</sub>	CF <sub>3</sub>
6.3	H	H	CH <sub>2</sub> CH <sub>2</sub> CH <sub>3</sub>	CH <sub>3</sub>
6.4	H	H	CH(CH <sub>3</sub> ) <sub>2</sub>	CF <sub>3</sub>
6.5	H	H	CH(CH <sub>3</sub> ) <sub>2</sub>	CH <sub>3</sub>
6.6	H	H	CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>3</sub>	CF <sub>3</sub>
6.7	H	H	CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>3</sub>	CH <sub>3</sub>
6.8	H	H	CH <sub>2</sub> CH(CH <sub>3</sub> ) <sub>2</sub>	CF <sub>3</sub>
6.9	H	H	CH <sub>2</sub> CH(CH <sub>3</sub> ) <sub>2</sub>	CH <sub>3</sub>
6.10	H	H	C(CH <sub>3</sub> ) <sub>3</sub>	CF <sub>3</sub>
6.11	H	H	C(CH <sub>3</sub> ) <sub>3</sub>	CH <sub>3</sub>
6.12	H	H	CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>3</sub>	CF <sub>3</sub>
6.13	H	H	CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>3</sub>	CH <sub>3</sub>
6.14	H	H	CH <sub>2</sub> CH <sub>2</sub> CH(CH <sub>3</sub> ) <sub>2</sub>	CF <sub>3</sub>
6.15	H	H	CH <sub>2</sub> CH <sub>2</sub> CH(CH <sub>3</sub> ) <sub>2</sub>	CH <sub>3</sub>
6.16	H	H	CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>3</sub>	CF <sub>3</sub>
6.17	H	H	CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CH <sub>3</sub>	CH <sub>3</sub>
6.18	H	H	cyclopropyl	CF <sub>3</sub>
6.19	H	H	cyclopropyl	CH <sub>3</sub>
6.20	H	H	cyclobutyl	CF <sub>3</sub>
6.21	H	H	cyclobutyl	CH <sub>3</sub>
6.22	H	H	cyclohexyl	CF <sub>3</sub>
6.23	H	H	cyclohexyl	CH <sub>3</sub>
6.24	H	H	cycloheptyl	CF <sub>3</sub>
6.25	F	F	cycloheptyl	CH <sub>3</sub>
6.26	H	H	cyclooctyl	CF <sub>3</sub>
6.27	H	H	cyclooctyl	CH <sub>3</sub>
6.28	F	F	cyclooctyl	CF <sub>3</sub>
6.29	H	H	phenyl	CF <sub>3</sub>

Compound Number	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>
6.30	H	H	phenyl	CH <sub>3</sub>
6.31	H	H	4-fluorophenyl	CF <sub>3</sub>
6.32	H	H	4-fluorophenyl	CH <sub>3</sub>
6.33	H	H	4-chlorophenyl	CF <sub>3</sub>
6.34	H	H	4-chlorophenyl	CH <sub>3</sub>
6.35	H	H	4-bromophenyl	CF <sub>3</sub>
6.36	H	H	2-thienyl	CF <sub>3</sub>
6.37	H	H	2-thienyl	CH <sub>3</sub>
6.38	H	H	3-thienyl	CF <sub>3</sub>
6.39	H	H	3-thienyl	CH <sub>3</sub>
6.40	H	H	2-furyl	CF <sub>3</sub>
6.41	H	H	3-furyl	CF <sub>3</sub>
6.42	H	H	2-pyridyl	CF <sub>3</sub>
6.43	H	H	4-pyridyl	CF <sub>3</sub>
6.44	H	H	$\alpha$ -methylcyclopropyl	CF <sub>3</sub>
6.45	H	H	$\alpha$ -methylcyclopropyl	CH <sub>3</sub>

Throughout this description, temperatures are given in degrees Celsius; "NMR" means nuclear magnetic resonance spectrum; MS stands for mass spectrum; and "%" is percent by weight, unless corresponding concentrations are indicated in other units.

5

The following abbreviations are used throughout this description:

m.p. = melting point

b.p.= boiling point.

S = singlet

br = broad

d = doublet

dd = doublet of doublets

t = triplet

q = quartet

m = multiplet

ppm = parts per million

Table 7 shows selected melting point and selected NMR data, all with CDCl<sub>3</sub> as the solvent (unless otherwise stated; if a mixture of solvents is present, this is indicated as, for example, (CDCl<sub>3</sub> / d<sub>6</sub>-DMSO)), (no attempt is made to list all characterising data

in all cases) for compounds of Tables 1 to 6. Unless otherwise stated, the data relate to a cis/trans mixture of each compound; a compound number which ends with the letter 'c' relates only to its cis-isomer and a compound number which ends with the letter 't' relates only to its trans-isomer.

5

Table 7

Compound Number	<sup>1</sup> H-NMR data: (ppm/multiplicity/number of Hs).	m.p. / (°C)
1.3	0.6-0.90/m/8H(cis and trans); 1.02/d/6H(cis); 1.11/6H(trans); 1.48/m/1H(trans); 1.78/m/1H(cis); 3.83/s/4H(NH <sub>2</sub> cis and trans); 6.68/m/4H(cis and trans); 7.0/m/4H(cis and trans).	oil
1.5	0.6-1.1/m/6H(cis and trans); 0.95-1.01/2d/12H(cis and trans); 1.25/m/2H(cis or trans); 1.40/m/2H(cis or trans); 1.78/m/2H(cis or trans); 3.85/s/4H(NH <sub>2</sub> cis and trans); 6.70/m/4H(cis and trans); 7.0/m/4H(cis and trans).	oil
1.6t	0.52/m/1H; 0.80/m/1H; 0.97/s/9H; 1.08/m/1H; 1.57/m/1H; 3.85/s/2H; 6.68/m/2H; 7.0/m/2H.	oil
1.10c	0.01/m/2H, 0.11/m/1H; 0.22/m/1H; 0.58/m/1H; 0.69/m/1H; 0.85/m/1H; 1.67/m/1H; 3.75/s/2H(NH <sub>2</sub> ); 6.49-6.60/m/2H; 6.82-7.00/m/2H.	oil
1.10t	0.01/m/2H; 0.30/m/2H; 0.55/m/2H; 0.72/m/2H; 1.28/m/1H; 3.70/s/2H(NH <sub>2</sub> ); 6.45-6.55/m/2H; 6.77-6.85/m/2H.	oil
1.12	0.75/m/4H (cis and trans); 0.97/m/2H (cis and trans); 1.3-1.95/m/20H (cis and trans); 3.88/s/4H (cis and trans); 6.68/m/4H (cis and trans); 7.01/m/4H (cis and trans).	oil
1.13	0.62-1.98/m/30H(cis and trans); 3.80/s/4H(cis and trans); 6.65/m/4H(cis and trans); 6.97/m/4H(cis and trans).	oil
1.17c		110-112
1.17t		69-70
1.18c	1.29/m/1H; 1.52/m/1H; 2.20/m/1H; 2.42/m/1H; 3.55/s/2H; 6.50/d/1H; 6.65-6.85/m/5H; 6.99/t/1H; 7.09/d/1H.	oil



1.18t		95-97
1.22c		60-62
1.22t	0.01-0.1/m/4H; 0.42/m/2H; 0.99/s/3H; 1.01/m/1H; 1.21/m/1H; 3.55/s/2H; 6.45/m/2H; 6.78/m/2H.	oil
2.5		99-102
2.17		75-78
2.18		74-79
2.23		134-136
2.24		110-112
2.33		88-92
2.34c		111-113
2.34t		116-118
2.35c		93-95
2.35t		134-136
2.45	0.6-1.90/m/30H(cis and trans); 4.0/s/6H(cis and trans); 7.0-7.28/m/6H(cis and trans); 8.0/s/1H(trans); 8.05/s/1H(cis); 8.12/d/2H(trans); 8.20/d/2H(cis).	resin
2.46t		116-118
2.52		116-118
2.54		129-131
2.57		107-109
2.66c		resin
2.66t		145-147
2.67c		104-106
2.67t		160-161
2.68c		resin
2.68t		148-150
2.69c		145-147
2.69t		149-150
2.76c		119-121


2.76t		107-108
2.77c		82-84
2.77t		109-111
2.78c		119-122
2.78t		96-97
3.5		74-78
3.17		61-65
3.23		92-96
3.33	-0.1-0.90/m/16H(cis and trans); 1.45/m/1H(trans); 1.79/m/1H(cis); 3.58/s/6H (cis and trans); 6.82-7.13/m/10H(cis and trans); 7.92/s/1 (NH-trans); 8.03/dd/1H(trans); 8.10/s/1H(NH-cis); 8.19/dd/1H (cis).	resin
3.39	0.63-1.83/m/26H(cis and trans); 3.72/s/6H(cis and trans); 6.95-7.38/m/10H(cis and trans); 8.05/s/1H(NH-trans); 8.18/dd/1H(trans); 8.30/dd/1H(cis).	resin
3.45	0.6-1.90/m/30H(cis and trans); 3.70/s/6H(cis and trans); 6.98-7.35/m/8H(cis and trans); 8.08/s(broad)/2H(cis and trans); 8.17/d/2H(trans); 8.25/d/2H(cis).	resin
3.66c	1.40/m/1H; 1.50-1.65/m/1H; 2.37/m/1H, 2.50/m/1H; 3.73/s/3H; 6.60-6.70/m/5H; 6.97/m/2H; 7.18/m/3H; 7.82/s/1H(NH); 8.02/d/1H.	resin
3.66t		146-148
3.68c	1.40/m/1H; 1.57/m/1H; 2.40/m/2H; 3.72/s/3H; 6.68/d/2H; 6.90-7.08/m/4H; 7.18/m/3H; 7.80/s/1H; 8.02/d/1H.	resin
3.68t		150-152
3.76		resin
3.80c		123-126
3.80t		94-96
4.10		69-74
4.12		resin

4.24		113-115
4.26		138-142
5.5		resin
5.12		83-86
5.21c		75-77
5.21t		80-82
5.25		131-133
5.28		115-119
5.37c		164-166
5.37t		133-135
5.40c		160-162
5.40t		136-138
5.53c	-0.25/m/1H; -0.01-0.03/m/3H; 0.60/s/3H; 0.65/m/1H; 0.79/m/1H; 1.25/m/1H; 1.80/m/1H; 6.95/t/1H; 7.08/m/2H; 7.28/m/1H; 8.15/d/2H; 8.38/m/1H; 8.62/s/1H(NH).	resin
5.53t	0.01/m/4H; 0.58/m/2H; 0.94/s/3H; 1.11/m/1H; 1.44/m/1H; 6.98/m/2H; 7.09/m/1H; 7.23/m/1H; 8.01/dd/1H; 8.10/d/1H; 8.35/dd/1H; 8.40/s/1H.	resin
6.10		resin


The compounds according to formula (I) may be prepared according to the following reaction schemes.

#### Scheme 1A

- 5 A compound of formula (II) [where  $R^3$  is as defined above for a compound of formula (I)] may be prepared by a reaction sequence starting with a crossed-aldol condensation of benzaldehyde with a ketone of formula  $CH_3C(O)R^3$  [where  $R^3$  is as defined above for a compound of formula (I)] in the presence of NaOH or KOH in a solvent (such as water or ethanol) and usually under reflux conditions or alternatively by
- 10 reaction of benzaldehyde with a Wittig reagent under standard conditions. The resulting  $\alpha,\beta$ -unsaturated ketone of formula (III) [where  $R^3$  is as defined above for a compound of formula (I)]:




may then be converted into a compound of formula (IV) [where  $R^3$  is as defined above for a compound of formula (I)]:



- 5 by reacting first with hydrazine hydrate in ethanol under reflux conditions and then heating (in the range 150 to 250<sup>0</sup>C) in the presence of KOH (distilling off the solvent). After nitration with HNO<sub>3</sub>/H<sub>2</sub>O or HNO<sub>3</sub>/acetic anhydride in a cooled vessel (in the range -30<sup>0</sup>C to 0<sup>0</sup>C), the resultant o/p-mixture of nitrobenzene of formula (V) [where  $R^3$  is as defined above for a compound of formula (I)]:


10



may then be separated and catalytically reduced (Pt/C/H<sub>2</sub> or Ra-Ni/H<sub>2</sub>) in a solvent (such as methanol, ethanol or THF) at room temperature, to produce a crude o/p-mixture of a compound of formula (II), which may be further purified by standard techniques.

15

Alternatively, a compound of formula (II) [where  $R^3$  is as defined above for a compound of formula (I)] may be prepared by a process as illustrated by the following reaction sequence and which involves a Pd(II)-catalysed imination step.

Scheme 1B

A compound of formula (VIII) [where  $R^3$  is as defined above for a compound of  
 5 formula (I)] is added to bromine and methanol at a temperature of 5-10°C, after which triphenylphosphine in a solvent [such as tetrahydrofuran] is added, to produce a compound of formula (IX) [where  $R^3$  is as defined above for a compound of formula (I)], which in turn is added to sodium hydride, in a solvent [such as DMSO], and then reacted with 2-bromobenzaldehyde or 2-iodobenzaldehyde to yield a compound of  
 10 formula (X) [where  $R^3$  is as defined above for a compound of formula (I) and Hal is bromo or iodo]. The resultant compound of formula (X) is then mixed with hydrazine hydrate in a solvent [such as ethanol] and heated to reflux, after which potassium hydroxide is added and the resultant reaction mixture is maintained at 200-220°C for several hours. A standard extraction and purification procedure yields a compound of  
 15 formula (XI) [where  $R^3$  is as defined above for a compound of formula (I) and Hal is bromo or iodo] which may then be converted to a compound of formula (II) by mixing with benzophenone imine, sodium tertiary butoxide, tris-dibenzylideneacetone-dipalladium ( $Pd_2dba_3$ ), racemic 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (BINAP) and a solvent [such as benzene or toluene] and heating at reflux temperature, typically  
 20 for several hours, and adding the resultant [usually crude isolated] imine to a mixture of hydroxylamine hydrochloride, sodium acetate and a solvent [such as methanol]. The resultant mixture is stirred, preferably for about an hour at room temperature, after which

a cis-/trans-mixture of a compound of formula (II) may be extracted and subsequent separation of the cis- and trans-isomers achieved by using flash chromatography.


In the above illustrated Pd-catalysed imination process, instead of the catalyst-ligand-system Pd<sub>2</sub>dba<sub>3</sub>/BINAP, the system palladium diacetate/1,1'-bis(diphenylphosphino)ferrocene (dppf) could be used as an alternative.

Reaction scheme 1B is novel and inventive, particularly the use of a Pd(II)-catalysed imination step. Therefore in a still further aspect the present invention provides a process for preparing a compound of formula (II), where R<sup>3</sup> is as defined above, comprising at least one of the steps of reaction scheme 1B; in particular a step using a Pd(II)catalyst-ligand-system [where the ligand is selected from a suitable sterically demanding phosphine (for example BINAP or dppf)] to react a compound of formula (XI) [where Hal is bromo or iodo; and R<sup>3</sup> is as defined above] with benzophenone imine optionally in the presence of a base [such as sodium-*tert*-butanolate, potassium-*tert*-butanolate, sodium carbonate, potassium carbonate or cesium carbonate] to produce a compound of formula (XII) [where R<sup>3</sup> is as defined above].


Examples of imination reactions with benzophenone imine are provided in the literature (Journal of Organometallic Chemistry, 1999, 576, 125-146 and Tetrahedron Letters 1997, 38, 6367-6370).

## Scheme 2

The synthesis of an amine of formula (IIA)



[where R<sup>3A</sup> is hydrogen or methyl] may be accomplished by a reaction sequence started by a Wittig reaction of o-nitrobenzaldehyde with an ylide [prepared from a cyclopropylmethytriphenylphosphonium bromide in the presence of a strong base, such as NaH in a solvent such as DMSO, in the range 0-85°C]. The resulting E/Z-mixture of a compound of formula (VI)



[where R<sup>3A</sup> is hydrogen or methyl] may be converted to a compound of formula (VII)




by the application of the Simmons Smith reaction (Zn/Cu, CH<sub>2</sub>I<sub>2</sub>, ether as solvent) to the olefin group of the compound of formula (VI). The reduction of the nitro group of the corresponding compound of formula (VII) may be performed using the conditions described in Scheme 1, to produce a compound of formula (IIA).

### Scheme 3


A compound of formula (I) may be prepared by reacting a compound of formula Het-C(=O)-R\* [where R\* is halogen, hydroxy or C<sub>1-6</sub> alkoxy, but preferably chloro] with a compound of formula (II) as prepared above in the presence of a base (such as triethylamine, Hunig base, sodium bicarbonate, sodium carbonate, potassium carbonate, pyridine or quinoline, but preferably triethylamine) and in a solvent (such as diethylether, TBME, THF, dichloromethane, chloroform, DMF or NMP) for between 10 minutes and 48 hours (preferably 12 to 24 hours) and between 0°C and reflux (preferably 20 to 25°C). When R\* is hydroxy, a coupling agent [such as benzotriazol-1-yloxytris(dimethylamino) phosphoniumhexafluorophosphate, bis-(2-oxo-3-oxazolidinyl)-phosphinic acid chloride, N,N'-dicyclohexylcarbodiimide or 1,1'-carbonyl-diimidazole] may be used.

### Scheme 4

A compound of formula (IA)



[where  $R^{3A}$  is hydrogen or methyl] may be prepared by the reduction of the nitro group of a compound of formula (VI) [where  $R^{3A}$  is hydrogen or methyl] using standard conditions (for example, catalytic reduction or Béchamp-reduction) followed by amidation with an acid chloride to provide a compound of formula (VII) [where  $R^{3A}$  is  
5 hydrogen or methyl]



which is subsequently used in a Simmons-Smith reaction ( $Zn/Cu, CH_2I_2$ , ether as solvent) to provide a compound of formula (IA).

Surprisingly, it has now been found that the novel compounds of formula (I) have,  
10 for practical purposes, a very advantageous spectrum of activities for protecting plants against diseases that are caused by fungi as well as by bacteria and viruses.

The compounds of formula (I) can be used in the agricultural sector and related fields of use as active ingredients for controlling plant pests. The novel compounds are distinguished by excellent activity at low rates of application, by being well tolerated by  
15 plants and by being environmentally safe. They have very useful curative, preventive and systemic properties and are used for protecting numerous cultivated plants. The compounds of formula I can be used to inhibit or destroy the pests that occur on plants or parts of plants (fruit, blossoms, leaves, stems, tubers, roots) of different crops of useful plants, while at the same time protecting also those parts of the plants that grow later e.g.  
20 from phytopathogenic microorganisms.

It is also possible to use compounds of formula (I) as dressing agents for the treatment of plant propagation material, in particular of seeds (fruit, tubers, grains) and plant cuttings (e.g. rice), for the protection against fungal infections as well as against phytopathogenic fungi occurring in the soil.

Furthermore the compounds according to present invention may be used for  
25 controlling fungi in related areas, for example in the protection of technical materials, including wood and wood related technical products, in food storage, in hygiene management, etc.



The compounds of formula (I) are, for example, effective against the phytopathogenic fungi of the following classes: Fungi imperfecti (e.g. Botrytis, Pyricularia, Helminthosporium, Fusarium, Septoria, Cercospora and Alternaria) and Basidiomycetes (e.g. Rhizoctonia, Hemileia, Puccinia). Additionally, they are also effective against the Ascomycetes classes (e.g. Venturia and Erysiphe, Podosphaera, Monilinia, Uncinula) and of the Oomycetes classes (e.g. Phytophthora, Pythium, Plasmopara). Outstanding activity has been observed against powdery mildew (Erysiphe spp.). Furthermore, the novel compounds of formula I are effective against phytopathogenic bacteria and viruses (e.g. against Xanthomonas spp, Pseudomonas spp, Erwinia amylovora as well as against the tobacco mosaic virus).

Within the scope of present invention, target crops to be protected typically comprise the following species of plants: cereal (wheat, barley, rye, oat, rice, maize, sorghum and related species); beet (sugar beet and fodder beet); pomes, drupes and soft fruit (apples, pears, plums, peaches, almonds, cherries, strawberries, raspberries and blackberries); leguminous plants (beans, lentils, peas, soybeans); oil plants (rape, mustard, poppy, olives, sunflowers, coconut, castor oil plants, cocoa beans, groundnuts); cucumber plants (pumpkins, cucumbers, melons); fibre plants (cotton, flax, hemp, jute); citrus fruit (oranges, lemons, grapefruit, mandarins); vegetables (spinach, lettuce, asparagus, cabbages, carrots, onions, tomatoes, potatoes, paprika); lauraceae (avocado, cinnamomum, camphor) or plants such as tobacco, nuts, coffee, eggplants, sugar cane, tea, pepper, vines, hops, bananas and natural rubber plants, as well as ornamentals.

The compounds of formula (I) are used in unmodified form or, preferably, together with the adjuvants conventionally employed in the art of formulation. To this end they are conveniently formulated in known manner to emulsifiable concentrates, coatable pastes, directly sprayable or dilutable solutions, dilute emulsions, wettable powders, soluble powders, dusts, granulates, and also encapsulations e.g. in polymeric substances. As with the type of the compositions, the methods of application, such as spraying, atomising, dusting, scattering, coating or pouring, are chosen in accordance with the intended objectives and the prevailing circumstances. The compositions may also contain further adjuvants such as stabilizers, antifoams, viscosity regulators, binders or tackifiers as well as fertilizers, micronutrient donors or other formulations for obtaining special effects.

Suitable carriers and adjuvants can be solid or liquid and are substances useful in formulation technology, e.g. natural or regenerated mineral substances, solvents, dispersants, wetting agents, tackifiers, thickeners, binders or fertilizers. Such carriers are for example described in WO 97/33890.

5           The compounds of formula (I) are normally used in the form of compositions and can be applied to the crop area or plant to be treated, simultaneously or in succession with further compounds. These further compounds can be e.g. fertilizers or micronutrient donors or other preparations which influence the growth of plants. They can also be selective herbicides as well as insecticides, fungicides, bactericides,  
10   nematicides, molluscicides or mixtures of several of these preparations, if desired together with further carriers, surfactants or application promoting adjuvants customarily employed in the art of formulation.

          The compounds of formula (I) can be mixed with other fungicides, resulting in some cases in unexpected synergistic activities. Mixing components which are  
15   particularly preferred are azoles, such as azaconazole, BAY 14120, bitertanol, bromuconazole, cyproconazole, difenoconazole, diniconazole, epoxiconazole, fenbuconazole, fluquinconazole, flusilazole, flutriafol, hexaconazole, imazalil, imibenconazole, ipconazole, metconazole, myclobutanil, pefurazoate, penconazole, pyrifenoxy, prochloraz, propiconazole, simeconazole, tebuconazole, tetraconazole, triadimefon,  
20   triadimenol, triflumizole, triticonazole; pyrimidinyl carbinole, such as ancymidol, fenarimol, nuarimol; 2-amino-pyrimidines, such as bupirimate, dimethirimol, ethirimol; morpholines, such as dodemorph, fenpropidine, fenpropimorph, spiroxamine, tridemorph; anilinopyrimidines, such as cyprodinil, mepanipyrim, pyrimethanil; pyrroles, such as fenpiclonil, fludioxonil; phenylamides, such as benalaxyl, furalaxyl,  
25   metalaxyl, R-metalaxyl, ofurace, oxadixyl; benzimidazoles, such as benomyl, carbendazim, debacarb, fuberidazole, thiabendazole; dicarboximides, such as chlozolate, dichlozoline, iprodione, myclozoline, procymidone, vinclozoline; carboxamides, such as carboxin, fenfuram, flutolanil, mepronil, oxycarboxin, thifluzamide; guanidines, such as guazatine, dodine, iminoctadine; strobilurines, such as  
30   azoxystrobin, kresoxim-methyl, metominostrobin, SSF-129, trifloxystrobin, picoxystrobin, BAS 500F (proposed name pyraclostrobin), BAS 520; dithiocarbamates, such as ferbam, mancozeb, maneb, metiram, propineb, thiram, zineb, ziram; N-

halomethylthiotetrahydrophthalimides, such as captafol, captan, dichlofluanid, fluoromides, folpet, tolyfluanid; Cu-compounds, such as Bordeaux mixture, copper hydroxide, copper oxychloride, copper sulfate, cuprous oxide, mancozeb, oxine-copper; nitrophenol-derivatives, such as dinocap, nitrothal-isopropyl; organo-p-derivatives, such as edifenphos, iprobenphos, isoprothiolane, phosdiphen, pyrazophos, tolclofos-methyl; various others, such as acibenzolar-S-methyl, anilazine, benthiavalicarb, blasticidin-S, chinomethionate, chloroneb, chlorothalonil, cyflufenamid, cymoxanil, dichlone, diclomezine, dicloran, diethofencarb, dimethomorph, SYP-LI90 (proposed name: flumorph), dithianon, ethaboxam, etridiazole, famoxadone, fenamidone, fenoxanil, fentin, ferimzone, fluazinam, flusulfamide, fenhexamid, fosetyl-aluminium, hymexazol, iprovalicarb, IKF-916 (cyazofamid), kasugamycin, methasulfocarb, metrafenone, nicobifen, pencycuron, phthalide, polyoxins, probenazole, propamocarb, pyroquilon, quinoxifen, quintozone, sulfur, triazoxide, tricyclazole, triforine, validamycin, zoxamide (RH7281).

A preferred method of applying a compound of formula (I), or an agrochemical composition which contains at least one of said compounds, is foliar application. The frequency of application and the rate of application will depend on the risk of infestation by the corresponding pathogen. However, the compounds of formula I can also penetrate the plant through the roots via the soil (systemic action) by drenching the locus of the plant with a liquid formulation, or by applying the compounds in solid form to the soil, e.g. in granular form (soil application). In crops of water rice such granulates can be applied to the flooded rice field. The compounds of formula I may also be applied to seeds (coating) by impregnating the seeds or tubers either with a liquid formulation of the fungicide or coating them with a solid formulation.

A formulation [that is, a composition containing the compound of formula (I)] and, if desired, a solid or liquid adjuvant, is prepared in a known manner, typically by intimately mixing and/or grinding the compound with extenders, for example solvents, solid carriers and, optionally, surface active compounds (surfactants).

The agrochemical formulations will usually contain from 0.1 to 99% by weight, preferably from 0.1 to 95% by weight, of the compound of formula I, 99.9 to 1% by weight, preferably 99.8 to 5% by weight, of a solid or liquid adjuvant, and from 0 to 25% by weight, preferably from 0.1 to 25% by weight, of a surfactant.

Advantageous rates of application are normally from 5g to 2kg of active ingredient (a.i.) per hectare (ha), preferably from 10g to 1kg a.i./ha, most preferably from 20g to 600g a.i./ha. When used as seed drenching agent, convenient dosages are from 10mg to 1g of active substance per kg of seeds.

5       Whereas it is preferred to formulate commercial products as concentrates, the end user will normally use dilute formulations.

The following non-limiting Examples illustrate the above-described invention in more detail.

#### EXAMPLE 1

10       This Example illustrates the preparation of Compound No. 1.5.

To a mixture of 17.4g (0.1mol) (2-isobutyl-cyclopropyl)benzene and 80ml of acetic acid anhydride was added a solution of 6.0g (0.095mol) nitric acid and 40ml acetic acid anhydride in such a manner that the internal temperature was kept constant at -30°C. The resulting reaction mixture was stirred for 1hour at -30°C and then for 2hours  
15       at 0°C. Then the mixture was poured onto 500ml of ice water and extracted three times with hexane. The hexane phases were combined and twice washed with 5% aqueous bicarbonate solution. After drying of the organic phase over sodium sulphate and distilling off the solvent in a water jet vacuum, the crude reaction product was obtained. Purification by flash chromatography over silica gel (eluant: ethylacetate/hexane 1:10)  
20       yielded 10.5g of a yellow oil (mixture of para- and ortho-nitroisomers) which was directly used in the next step. This isomeric mixture [consisting of 10.5g (0.048mol) 1-(2-isobutyl-cyclopropyl)2-nitrobenzene and 1-(2-isobutyl-cyclopropyl)-4-nitrobenzene] was dissolved in 110ml of ethanol and hydrogenated over 5%Pt/C catalyst for 45minutes. After the theoretical uptake of hydrogen had occurred, the catalyst was  
25       filtered off and the solvent was removed in vacuo. The crude isomeric aniline mixture was purified by flash chromatography (eluant: ethylacetate/hexane 1:2).

Yield: 6.38g of 2-(2-isobutyl-cyclopropyl)phenyl amine was obtained as a yellow oil (cis/trans mixture).

#### EXAMPLE 2

30       This Example illustrates the preparation of Compound 3.17.

A solution of 0.35g (0.0018mol) 1-methyl-4-trifluoromethyl-pyrrole-3-carboxylic acid and 0.24g (0.0019mol) oxalylchloride in 15ml methylenechloride was stirred for

3hours at room temperature in the presence of two drops of absolute DMF. Then the acid chloride solution was slowly added to a solution of 0.34g (0.0018mol) 2-(2-isobutyl-cyclopropyl) phenylamine, 0.27g (0.0027mol) triethylamine and 10ml methylene chloride. The resulting mixture was then stirred for 16hours at room temperature. After removal of the solvent in vacuo, the crude material was taken up in ca. 100ml ethylacetate. The ethylacetate phase was twice washed with water and after drying the organic phase, the solvent was again distilled off in a water jet vacuum. The crude product was purified by flash chromatography (eluant: hexane/ethylacetate/methylene chloride 1:2:2).

Yield: 0.52g 1-methyl-4-trifluoromethyl-1H-pyrrole-3-carboxylic acid [2-(2-isobutyl-cyclopropyl)phenyl]amide in the form of a white powder (cis/trans-mixture).

### EXAMPLE 3

This Example illustrates the preparation of Compound Nos. 1.10c and 1.10t.

#### Step 1:

In a sulfonation flask, NaH (12.8g; 0.32mol) was added to absolute DMSO (600ml). After heating at 80°C for 90minutes, cyclopropylcarbonylmethyltriphenyl phosphoniumbromide (136.5g; 0.32mol) was added portionwise at room temperature. The resultant suspension was stirred for 30minutes at room temperature and then a solution of 2-bromobenzaldehyde (59.4g; 0.32mol) in absolute DMSO (100ml) was added dropwise. After heating the resultant mixture for 4hours at 50°C, the mixture was poured onto 2.5litres of ice water. Extraction with ethylacetate, drying over sodium sulfate and distilling off the solvent in a water jet vacuum yielded the crude product. Purification was achieved by vacuum distillation.

Yield: 77.6g of E-3-(2-bromophenyl)-1-cyclopropylpropenone as a yellow oil (b.p.: 125-130°C at 0.3mbar).

#### Step 2:

In a sulfonation flask, a mixture of of E-3-(2-bromophenyl)-1-cyclopropylpropenone (77.6g; 0.309mol) and hydrazine hydrate (23.2g; 0.464mol) in ethanol (25ml) was heated at reflux temperature for 2hours. Then powdered potassium hydroxide (85%) (24.4g; 0.37mol) was added and the excesses of hydrazine hydrate and solvent were distilled out of the flask. The remaining mixture was then heated at a

temperature of 205-210°C for 3 hours. The resultant resin was dissolved in ethylacetate (500ml) at a temperature of 50°C and the organic phase was washed twice with water. Drying of the ethylacetate phase over sodium sulfate and distilling off the solvent in a water jet vacuum gave the raw material, which was purified by flash chromatography over silica gel (eluant: hexane/methylene chloride 7:1).

Yield: 61.2g of 2-(2-bromophenyl)bicyclopropyl in the form of a slightly yellowish oil (cis/trans-mixture).

**Step 3:**

A mixture of 2-(2-bromophenyl)bicyclopropyl (28.5g; 0.12mol), benzophenoneimine (26.1g; 0.144mol), sodium tertiary butoxide (16.1g; 0.168 mol), tris-dibenzyl-ideneacetone dipalladium ( $\text{Pd}_2\text{dba}_3$ ) (0.43g; 0.474mmol), racemic 2,2'-bis(diphenylphosphino)1,1'-binaphthyl (BINAP) (0.83g; 1.34mmol) and absolute toluene (450ml) was heated at reflux temperature under an atmosphere of nitrogen for 6 hours. Then the solvent was removed in a water jet vacuum and the residue was taken up in ethylacetate (750ml). The organic layer was washed three times with brine and then dried over sodium sulfate. After evaporation of the solvent, the crude product was obtained. Purification was achieved by using flash chromatography over silica gel (eluant: hexane/methylene chloride 5:1).

Yield: 39.9g of cis-/trans-mixture of benzhydrylidene (2-bi-cyclopropyl-2-yl-phenyl)amine in the form of a brownish oil.

**Step 4:**

In a sulfonation flask, hydroxylamine hydrochloride (0.35g; 0.0048mol), sodium acetate (0.53g; 0.0064mol) and absolute methanol (30ml) were stirred at room temperature for about 15 minutes. Then a solution of benzhydrylidene (2-bicyclopropyl-2-yl-phenyl)amine (0.9g; 0.00267 mol) in methanol (15ml) was added dropwise. The resultant mixture was stirred for 1 hour at room temperature. After dilution with ethylacetate (250ml), the organic phase was washed twice with water. After drying the organic phase (sodium sulfate) and distilling off the solvent in a water jet vacuum, the crude product was obtained. The final purification and separation of the cis- and trans-isomers was achieved by using flash chromatography (eluant: hexane/ethylacetate 5:1).

Yield: 0.21g of trans- and 0.15g of cis- 2-bicyclopropyl-2-yl-phenylamine in the form of brownish oils.

#### FORMULATION EXAMPLES FOR COMPOUNDS OF FORMULA (I)

Working procedures for preparing formulations of the compounds of formula I such as Emulsifiable concentrates, Solutions, Granulates, Dusts and Wettable powders are described in WO 97/33890.

#### BIOLOGICAL EXAMPLES: FUNGICIDAL ACTIONS

##### Example B-1: Action against *Puccinia recondita* / wheat (Brownrust on wheat)

1 week old wheat plants cv. Arina are treated with the formulated test compound (0.02% active ingredient) in a spray chamber. One day after application wheat plants are inoculated by spraying a spore suspension ( $1 \times 10^5$  uredospores/ml) on the test plants. After an incubation period of 2 days at 20°C and 95% r. h. plants are kept in a greenhouse for 8 days at 20°C and 60% r.h. The disease incidence is assessed 10 days after inoculation.

Compounds of Tables 2, 3, 4 and 5 show good activity in this test (<20% infestation). Infestation is prevented virtually completely (0-5% infestation) with each of compounds 2.5, 2.17, 2.18, 2.23, 2.24, 2.33, 2.45, 2.46t, 2.76c, 2.76t, 2.77c, 2.77t, 3.5, 3.17, 3.23, 3.33, 3.45, 3.76, 4.10, 4.12, 4.26, 5.5, 5.12, 5.21c and 5.37c.

##### Example B-2: Action against *Podosphaera leucotricha* / apple (Powdery mildew on apple)

5 week old apple seedlings cv. McIntosh are treated with the formulated test compound (0.002% active ingredient) in a spray chamber. One day after application apple plants are inoculated by shaking plants infected with apple powdery mildew above the test plants. After an incubation period of 12 days at 22°C and 60% r.h. under a light regime of 14/10 hours (light/dark) the disease incidence is assessed.

Compounds of Tables 2, 3 and 4 show good activity in this test. The compounds 2.5, 2.17, 2.18, 2.23, 2.24, 2.33, 2.45, 2.46t, 3.5, 3.17, 3.23, 3.33, 3.45, 4.10 and 4.12 each exhibit strong efficacy (<20% infestation).

##### Example B-3: Action against *Venturia inaequalis* / apple (Scab on apple)

4 week old apple seedlings cv. McIntosh are treated with the formulated test compound (0.02% active ingredient) in a spray chamber. One day after application apple plants are inoculated by spraying a spore suspension ( $4 \times 10^5$  conidia/ml) on the test plants. After an incubation period of 4 days at 21°C and 95%r.h. the plants are placed for 4 days at 21°C and 60%r.h. in a greenhouse. After another 4 day incubation period at 21°C and 95%r.h. the disease incidence is assessed.

Compounds of Tables 2 and 3 show good activity in this test. The compounds 2.5, 2.17, 2.18, 2.23, 2.24, 2.33, 2.45, 2.46t, 3.5, 3.17, 3.23, 3.33 and 3.45 each exhibit strong efficacy

(<20% infestation).

**Example B-4: Action against *Erysiphe graminis* / barley (Powdery mildew on barley)**

1 week old barley plants cv. Express are treated with the formulated test compound (0.02% active ingredient) in a spray chamber. One day after application barley plants are inoculated by shaking powdery mildew infected plants above the test plants. After an incubation period of 6 days at 20°C / 18°C (day/night) and 60%r. h. in a greenhouse the disease incidence is assessed.

Compounds of Tables 2, 3 and 4 show good activity in this test. The compounds 2.5, 2.17, 2.18, 2.23, 2.24, 2.45, 2.46t, 2.77c, 2.77t, 3.5, 3.17, 3.23, 3.45, 4.10 and 4.12 each exhibit strong efficacy (<20% infestation).

**Example B-5: Action against *Botrytis cinerea* / apple (Botrytis on apple fruits)**

In an apple fruit cv. Golden Delicious 3 holes are drilled and each filled with 30µl droplets of the formulated test compound (0.002% active ingredient). Two hours after application 50 µl of a spore suspension of *B. cinerea* ( $4 \times 10^5$  conidia/ml) are pipetted on the application sites. After an incubation period of 7 days at 22°C in a growth chamber the disease incidence is assessed.

Compounds of Tables 2, 3, 4, 5 and 6 show good activity in this test. The compounds 2.5, 2.17, 2.18, 2.23, 2.24, 2.33, 2.45, 2.46t, 2.76c, 2.76t, 2.77c, 2.77t, 3.5, 3.17, 3.23, 3.33, 3.76, 3.45, 3.76, 4.10, 4.12, 4.26, 5.5, 5.12, 5.21c and 5.37 each exhibit very strong efficacy (<10% infestation).

**Example B-6: Action against *Botrytis cinerea* / grape (Botrytis on grapes)**

5 week old grape seedlings cv. Gutedel are treated with the formulated test compound (0.002% active ingredient) in a spray chamber. Two days after application



grape plants are inoculated by spraying a spore suspension ( $1 \times 10^6$  conidia/ml) on the test plants. After an incubation period of 4 days at 21°C and 95%r.h. in a greenhouse the disease incidence is assessed.

Compounds of Tables 2, 3, 4, 5 and 6 show good activity in this test. The  
5 compounds 2.5, 2.17, 2.18, 2.23, 2.24, 2.45, 2.46t, 2.76c, 2.76t, 2.77c, 2.77t, 3.5, 3.17, 3.23, 3.33, 3.39, 3.76, 4.10, 4.12, 4.26, 5.5, 5.12, 5.21c and 5.37c each exhibit very strong efficacy (<10% infestation).

Example B-7: Action against *Botrytis cinerea* / tomato (Botrytis on tomatoes)

4 week old tomato plants cv. Roter Gnom are treated with the formulated test  
10 compound (0.002% active ingredient) in a spray chamber. Two days after application tomato plants are inoculated by spraying a spore suspension ( $1 \times 10^5$  conidia/ml) on the test plants. After an incubation period of 4 days at 20°C and 95%r.h. in a growth chamber the disease incidence is assessed.

Compounds of Tables 2, 3, 4, 5 and 6 show good activity in this test. The  
15 compounds 2.5, 2.17, 2.18, 2.23, 2.24, 2.33, 2.45, 2.46t, 2.76c, 2.76t, 2.77c, 2.77t, 3.5, 3.17, 3.23, 3.39, 3.45, 3.76, 4.10, 4.12, 4.26, 5.5, 5.12, 5.21c and 5.37c each exhibit very strong efficacy (<10% infestation).

Example B-8: Action against *Pyrenophora teres* / barley (Net blotch on barley)

1 week old barley plants cv. Express are treated with the formulated test compound  
20 (0.002% active ingredient) in a spray chamber. Two days after application barley plants are inoculated by spraying a spore suspension ( $3 \times 10^4$  conidia/ml) on the test plants. After an incubation period of 2 days at 20°C and 95%r.h. plants are kept for 2 days at 20°C and 60%r.h. in a greenhouse. The disease incidence is assessed 4 days after inoculation.

Compounds of Tables 2, 3, 4, 5 and 6 show good activity in this test. The  
25 compounds 2.5, 2.17, 2.18, 2.23, 2.24, 2.33, 2.45, 2.46t, 2.76c, 2.76t, 2.77c, 2.77t, 3.5, 3.17, 3.23, 3.39, 3.45, 3.76, 4.10, 4.12, 4.26, 5.5, 5.12, 5.21c and 5.37c each exhibit very strong efficacy (<20% infestation).

Example B-9: Action against *Septoria nodorum* / wheat (Septoria leaf spot on wheat)


1 week old wheat plants cv. Arina are treated with the formulated test compound  
30 (0.02% active ingredient) in a spray chamber. One day after application wheat plants are inoculated by spraying a spore suspension ( $5 \times 10^5$  conidia/ml) on the test plants. After an

incubation period of 1 day at 20°C and 95%r.h. plants are kept for 10 days at 20°C and 60%r.h. in a greenhouse. The disease incidence is assessed 11 days after inoculation.

Compounds of Tables 2, 3 and 4 show good activity in this test. The compounds 2.5, 2.17, 2.18, 2.23, 2.24, 2.33, 2.45, 2.46t, 2.76c, 2.76t, 2.77c, 2.77t, 3.5, 3.17, 3.23, 5 3.33, 3.39, 3.45, 3.76, 4.10 and 4.12 each exhibit strong efficacy (<20% infestation).

CLAIMS

1. A compound of formula (I):




Het is a 5- or 6-membered heterocyclic ring containing one to three heteroatoms,  
each independently selected from oxygen, nitrogen and sulphur, the ring being  
substituted by groups  $R^4$ ,  $R^5$  and  $R^6$ ;  $R^1$  is hydrogen or halo;  $R^2$  is hydrogen or  
halo;  $R^3$  is optionally substituted  $C_{2-12}$  alkyl, optionally substituted  $C_{2-12}$  alkenyl,  
optionally substituted  $C_{2-12}$  alkynyl, optionally substituted  $C_{3-12}$  cycloalkyl,  
optionally substituted phenyl or optionally substituted heterocyclyl; and  $R^4$ ,  $R^5$   
and  $R^6$  are, independently, selected from hydrogen, halo, cyano, nitro,  $C_{1-4}$  alkyl,  
 $C_{1-4}$  haloalkyl,  $C_{1-4}$  alkoxy( $C_{1-4}$ )alkyl and  $C_{1-4}$  haloalkoxy( $C_{1-4}$ )alkyl, provided  
that at least one of  $R^4$ ,  $R^5$  and  $R^6$  is not hydrogen.

2. A compound of formula (I) as claimed in claim 1 where Het is pyrrolyl,  
pyrazolyl, thiazolyl, pyridinyl, pyrimidinyl, thiophenyl, furyl, isothiazolyl or  
isoxazolyl, each being substituted by groups  $R^4$ ,  $R^5$  and  $R^6$ .
3. A compound of formula (I) as claimed in claim 1 or 2 where  $R^1$  is hydrogen or  
fluoro.
4. A compound of formula (I) as claimed in claim 1, 2 or 3 where  $R^2$  is hydrogen or  
fluoro.
5. A compound of formula (I) as claimed in claim 1, 2, 3 or 4 where  $R^3$  is  
 $C_{2-6}$  alkyl, optionally substituted  $C_{3-8}$  cycloalkyl, phenyl, thienyl or furyl.


6. A compound of formula (I) as claimed in claim 1, 2, 3, 4 or 5 where  $R^4$ ,  $R^5$  and  $R^6$  are, independently, selected from hydrogen, halogen,  $C_{1-4}$  alkyl,  $C_{1-4}$  haloalkyl and  $C_{1-4}$  alkoxy( $C_{1-4}$ )alkyl; provided that at least one of  $R^4$ ,  $R^5$  and  $R^6$  is not hydrogen.

7. A compound of formula (II):




where  $R^3$  is as defined in claim 1 or 5.

8. A process for preparing a compound of formula (II) as claimed in claim 7 which comprises a step using a Pd(II)catalyst-ligand-system where the ligand is selected from a suitable sterically demanding phosphine to react a compound of formula (XI)



with benzophenone imine optionally in the presence of a base to produce a compound of formula (XII)



where Hal is bromo or iodo; and  $R^3$  is as defined in claim 7.

9. A composition for controlling microorganisms and preventing attack and infestation of plants therewith, wherein the active ingredient is a compound of formula (I) as claimed in claim 1 together with a suitable carrier.
- 5 10. A method of controlling or preventing infestation of cultivated plants by phytopathogenic microorganisms by application of a compound of formula (I) as claimed in claim 1 to plants, to parts thereof or the locus thereof.

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/IB 03/00687

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D231/14 C07D231/16 C07D409/12 C07D405/12 C07D207/34  
 C07D277/56 C07D417/12 C07D213/82 C07D327/06 C07D411/12  
 A01N43/56 A01N43/36 A01N43/78 A01N43/40 A01N43/32

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D C07C A01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BEILSTEIN Data, WPI Data, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 545 099 A (BASF AKTIENGESSELLSCHAFT) 9 June 1993 (1993-06-09) cited in the application the whole document ---	1-10
X	WO 01 53259 A (SYNGENTA PARTICIPATIONS AG) 26 July 2001 (2001-07-26) the whole document ---	1-10
X	DATABASE WPI Section Ch, Week 199026 Derwent Publications Ltd., London, GB; Class C02, AN 1990-196872 XP002241837 -& JP 02 129171 A (NISSAN CHEM IND LTD), 17 May 1990 (1990-05-17) cited in the application abstract -----	1-10

☐ Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

20 May 2003

Date of mailing of the international search report

10/06/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

Allard, M

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/IB 03/00687

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D333/20 C07D307/52 C07C211/45

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.

☐ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \* & \* document member of the same patent family

Date of the actual completion of the international search

20 May 2003

Date of mailing of the international search report

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Allard, M

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/JP03/00687

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 545099	A	09-06-1993	AT 149487 T 15-03-1997
			AU 656243 B2 27-01-1995
			AU 2855492 A 27-05-1993
			CA 2081935 A1 23-05-1993
			CZ 9203448 A3 13-10-1993
			CZ 289478 B6 16-01-2002
			DE 59208113 D1 10-04-1997
			DK 545099 T3 24-03-1997
			EP 0545099 A2 09-06-1993
			ES 2098421 T3 01-05-1997
			GR 3023336 T3 29-08-1997
			HU 62861 A2 28-06-1993
			IL 103614 A 24-09-1998
			JP 3202079 B2 27-08-2001
			JP 5221994 A 31-08-1993
			JP 2001253802 A 18-09-2001
			JP 2001316210 A 13-11-2001
			KR 267518 B1 16-10-2000
			NZ 245194 A 27-02-1996
			PL 296677 A1 18-10-1993
			SK 344892 A3 08-03-1995
			US 5480897 A 02-01-1996
			US 5556988 A 17-09-1996
			US 5589493 A 31-12-1996
			US 5330995 A 19-07-1994
			ZA 9208977 A 19-05-1994
WO 0153259	A	26-07-2001	AU 3543301 A 31-07-2001
			BR 0107738 A 22-10-2002
			CA 2397008 A1 26-07-2001
			CZ 20022496 A3 16-10-2002
			WO 0153259 A1 26-07-2001
			EP 1252140 A1 30-10-2002
JP 2129171	A	17-05-1990	HU 0203960 A2 28-03-2003
			NONE